Home/Filings/4/0001012975-19-000199

4//SEC Filing

ARCH Venture Partners X, LLC 4

Accession 0001012975-19-000199

CIK 0001656328other

View on SEC.gov Company Profile

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 9:08 PM ET

Size

21.3 KB

Accession

0001012975-19-000199

Insider Transaction Report

Form 4

Period: 2019-02-22

Sienna Biopharmaceuticals, Inc.SNNA

ARCH Venture Partners X, LLC

10% Owner

Transactions

Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 2,900,575 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 1,032,493 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+1,865,800$4,664,500→ 1,865,800 total(indirect: See footnote)

ARCH Venture Fund X Overage, L.P.

10% Owner

Transactions

Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 2,900,575 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 1,032,493 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+1,865,800$4,664,500→ 1,865,800 total(indirect: See footnote)

ARCH Venture Partners X Overage, L.P.

10% Owner

Transactions

Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 2,900,575 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 1,032,493 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+1,865,800$4,664,500→ 1,865,800 total(indirect: See footnote)

CRANDELL KEITH

10% Owner

Transactions

Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 1,032,493 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 2,900,575 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+1,865,800$4,664,500→ 1,865,800 total(indirect: See footnote)

NELSEN ROBERT

Director10% Owner

Transactions

Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 1,032,493 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+1,865,800$4,664,500→ 1,865,800 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 2,900,575 total(indirect: See footnote)

GILLIS STEVEN

10% Owner

Transactions

Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 2,900,575 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+150,000$375,000→ 1,032,493 total(indirect: See footnote)
Purchase
Common Stock
2019-02-22$2.50/sh+1,865,800$4,664,500→ 1,865,800 total(indirect: See footnote)

Footnotes (3)

[F1]Following the transactions reported herein, includes 1,032,493 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"), 2,900,575 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"), and 1,865,800 shares of common stock held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage").
[F2]The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
[F3]The sole general Partner of ARCH X Overage is ARCH Venture Partners X Overage, L.P. ("AVP X Over GP"). The sole general partner of AVP X Over GP is ARCH Venture Partners X, LLC ("AVP X LLC"). AVP X Over LP and AVP X LLC may therefore be deemed to beneficially own the securities held by ARCH X Overage. AVP X Over GP and AVP X LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Keith L. Crandell, Robert Nelsen and Steven Gillis are managing directors of AVP X LLC, and they may be deemed to beneficially own the shares held by ARCH X Overage. Messrs. Crandell, Nelsen and Gillis disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Documents

2 files

Issuer

Sienna Biopharmaceuticals, Inc.

CIK 0001656328

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001769012

Filing Metadata

Form type: 4
Filed: Feb 25, 7:00 PM ET
Accepted: Feb 26, 9:08 PM ET
Size: 21.3 KB

View on SEC.gov